Research Analysts Offer Predictions for TRVI FY2024 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Stock analysts at Leerink Partnrs dropped their FY2024 EPS estimates for Trevi Therapeutics in a note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($0.48) for the year, down from their previous estimate of ($0.46). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.47) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q4 2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.49) EPS.

TRVI has been the topic of several other research reports. B. Riley reiterated a “buy” rating and issued a $6.00 target price on shares of Trevi Therapeutics in a research report on Monday, October 7th. Leerink Partners began coverage on shares of Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Trevi Therapeutics in a research note on Friday, October 4th. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, August 19th. Finally, HC Wainwright assumed coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They set a “buy” rating and a $6.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $7.43.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $3.12 on Friday. The company’s 50-day simple moving average is $3.08 and its 200-day simple moving average is $2.89. Trevi Therapeutics has a 52-week low of $0.97 and a 52-week high of $4.00. The firm has a market cap of $219.76 million, a price-to-earnings ratio of -9.18 and a beta of 0.97.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter last year, the business posted ($0.07) EPS.

Institutional Investors Weigh In On Trevi Therapeutics

A number of large investors have recently modified their holdings of TRVI. Oppenheimer & Co. Inc. purchased a new stake in shares of Trevi Therapeutics in the 1st quarter valued at approximately $208,000. Vanguard Group Inc. increased its position in shares of Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after purchasing an additional 60,249 shares during the last quarter. Propel Bio Management LLC purchased a new stake in shares of Trevi Therapeutics in the 1st quarter valued at approximately $897,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Trevi Therapeutics in the 1st quarter valued at approximately $47,000. Finally, Opaleye Management Inc. increased its position in shares of Trevi Therapeutics by 4.3% in the 1st quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company’s stock valued at $9,125,000 after purchasing an additional 110,000 shares during the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Trevi Therapeutics

In related news, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares in the company, valued at approximately $644,205.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the transaction, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at $644,205.26. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,355 shares of company stock worth $116,663. Corporate insiders own 24.37% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.